Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced that their preclinical study abstract for KIO-104 in treating proliferative vitreoretinopathy (PVR) will be presented at the ARVO 2025 Annual Meeting in Salt Lake City. The study demonstrates KIO-104's potential as a therapeutic candidate for both preventing and treating PVR.
The presentation, titled 'KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model,' will showcase research evaluating multiple dose levels' effectiveness in reducing scar formation and magnitude in a retinal detachment model. KIO-104 functions by suppressing T cell division and function, potentially offering a new approach to reducing inflammation that leads to scar formation.
Currently, there are no approved treatments for PVR, a condition characterized by scar formation and retinal detachment following eye surgery or trauma. KIO-104 is simultaneously undergoing Phase 2 clinical trials for macular edema treatment.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha annunciato che il loro abstract dello studio preclinico per KIO-104 nel trattamento della vitreoretinopatia proliferativa (PVR) sarà presentato al Meeting Annuale ARVO 2025 a Salt Lake City. Lo studio dimostra il potenziale di KIO-104 come candidato terapeutico sia per prevenire che per trattare la PVR.
La presentazione, intitolata 'KIO-104, un nuovo inibitore a piccole molecole di DHODH, previene efficacemente la vitreoretinopatia proliferativa in un modello di coniglio,' metterà in evidenza la ricerca che valuta l'efficacia di diversi livelli di dosaggio nella riduzione della formazione di cicatrici e della loro grandezza in un modello di distacco retinico. KIO-104 agisce sopprimendo la divisione e la funzione delle cellule T, offrendo potenzialmente un nuovo approccio per ridurre l'infiammazione che porta alla formazione di cicatrici.
Attualmente, non ci sono trattamenti approvati per la PVR, una condizione caratterizzata dalla formazione di cicatrici e dal distacco retinico a seguito di interventi chirurgici oculari o traumi. KIO-104 è contemporaneamente in fase di sperimentazione clinica di Fase 2 per il trattamento dell'edema maculare.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha anunciado que su resumen del estudio preclínico para KIO-104 en el tratamiento de la vitreoretinopatía proliferativa (PVR) se presentará en la Reunión Anual ARVO 2025 en Salt Lake City. El estudio demuestra el potencial de KIO-104 como candidato terapéutico tanto para prevenir como para tratar la PVR.
La presentación, titulada 'KIO-104, un nuevo inhibidor de pequeñas moléculas de DHODH, previene eficazmente la vitreoretinopatía proliferativa en un modelo de conejo,' mostrará la investigación que evalúa la efectividad de múltiples niveles de dosis en la reducción de la formación y magnitud de cicatrices en un modelo de desprendimiento de retina. KIO-104 funciona suprimiendo la división y función de las células T, ofreciendo potencialmente un nuevo enfoque para reducir la inflamación que conduce a la formación de cicatrices.
Actualmente, no hay tratamientos aprobados para la PVR, una condición caracterizada por la formación de cicatrices y el desprendimiento de retina tras cirugía ocular o trauma. KIO-104 se encuentra simultáneamente en ensayos clínicos de Fase 2 para el tratamiento del edema macular.
Kiora Pharmaceuticals (NASDAQ: KPRX)는 KIO-104의 전임상 연구 초록이 2025년 ARVO 연례 회의에서 발표될 것이라고 발표했습니다. 이 연구는 PVR 예방 및 치료를 위한 치료 후보로서 KIO-104의 잠재력을 보여줍니다.
'KIO-104, DHODH의 새로운 소분자 억제제, 토끼 모델에서 PVR을 효과적으로 예방하다'라는 제목의 발표는 망막 박리 모델에서 흉터 형성과 크기를 줄이는 데 있어 여러 용량 수준의 효과를 평가하는 연구를 소개할 것입니다. KIO-104는 T 세포의 분열과 기능을 억제함으로써 흉터 형성으로 이어지는 염증을 줄이는 새로운 접근 방식을 제공할 수 있습니다.
현재 PVR에 대한 승인된 치료법은 없으며, 이는 안과 수술이나 외상 후 흉터 형성과 망막 박리로 특징지어지는 상태입니다. KIO-104는 동시에 황반 부종 치료를 위한 2상 임상 시험을 진행 중입니다.
Kiora Pharmaceuticals (NASDAQ: KPRX) a annoncé que leur résumé d'étude préclinique pour KIO-104 dans le traitement de la vitréorétinopathie proliférante (PVR) sera présenté lors de la Réunion Annuelle ARVO 2025 à Salt Lake City. L'étude démontre le potentiel de KIO-104 en tant que candidat thérapeutique pour prévenir et traiter la PVR.
La présentation, intitulée 'KIO-104, un nouvel inhibiteur de petites molécules de DHODH, prévient efficacement la vitréorétinopathie proliférante dans un modèle de lapin,' mettra en avant la recherche évaluant l'efficacité de plusieurs niveaux de dosage pour réduire la formation et la magnitude des cicatrices dans un modèle de décollement de rétine. KIO-104 agit en supprimant la division et la fonction des cellules T, offrant potentiellement une nouvelle approche pour réduire l'inflammation qui conduit à la formation de cicatrices.
Actuellement, il n'existe aucun traitement approuvé pour la PVR, une condition caractérisée par la formation de cicatrices et le décollement de la rétine à la suite d'une chirurgie oculaire ou d'un traumatisme. KIO-104 est simultanément en phase d'essai clinique de phase 2 pour le traitement de l'œdème maculaire.
Kiora Pharmaceuticals (NASDAQ: KPRX) hat bekannt gegeben, dass ihr Abstract der präklinischen Studie für KIO-104 zur Behandlung der proliferativen Vitreoretinopathie (PVR) auf dem ARVO-Jahrestreffen 2025 in Salt Lake City präsentiert wird. Die Studie zeigt das Potenzial von KIO-104 als therapeutischen Kandidaten zur Prävention und Behandlung von PVR.
Die Präsentation mit dem Titel 'KIO-104, ein neuartiger kleiner Molekülinhibitor von DHODH, verhindert effektiv die proliferative Vitreoretinopathie in einem Kaninchenmodell,' wird die Forschung vorstellen, die die Wirksamkeit mehrerer Dosierungsstufen bei der Reduzierung der Narbenbildung und -größe in einem Modell für Netzhautablösung bewertet. KIO-104 wirkt, indem es die Teilung und Funktion von T-Zellen unterdrückt, was potenziell einen neuen Ansatz zur Verringerung der Entzündung bietet, die zur Narbenbildung führt.
Derzeit gibt es keine zugelassenen Behandlungen für PVR, eine Erkrankung, die durch Narbenbildung und Netzhautablösung nach Augenoperationen oder Trauma gekennzeichnet ist. KIO-104 befindet sich gleichzeitig in klinischen Phase-2-Studien zur Behandlung von Makulaödem.
- First potential treatment for PVR, addressing an unmet medical need
- Successful preclinical results showing effectiveness in PVR prevention
- Dual development potential: PVR prevention and macular edema treatment
- Still in early preclinical stage for PVR indication
- No clinical efficacy data available yet for PVR treatment
Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
The presentation, titled, "KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model," will be presented by Romana Seda-Zehetner, MSc MSc Tox, Kiora's Director, Preclinical Development. The study evaluated the effect of KIO-104 at multiple dose levels on the reduction of both scar formation and magnitude in an established model of retinal detachment. Clinically, PVR is characterized by scar formation and subsequent retinal detachment. This complication of retinal surgery and/or eye trauma is believed to be driven by abnormal levels of inflammation and proliferation of cells normally involved in retinal tissue repair and can lead to repeated retinal detachments and progressive loss of vision. There are currently no available approved treatment options for PVR.
KIO-104 is a small molecule DHODH inhibitor that works by suppressing T cell division and function. Suppressing T cells in PVR could provide a novel approach to reducing or eliminating inflammation that often leads to scar formation. KIO-104 is being evaluated in a Phase 2 clinical trial in patients with macular edema, an inflammation driven condition secondary to several conditions including diabetic retinopathy and posterior non-infectious uveitis.
Presentation details:
Presentation #: 218 - A0485
Session Title: Vitreoretinal surgery and retinal detachment I
Date: May 4, 2025
Time: 8:00 AM to 9:45 AM Mountain Standard Time
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from clinical trials of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, the anticipated readout dates for Kiora's clinical trials and their likelihood of success, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on November 8, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
###
Contact:
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244295
FAQ
What are the key findings of Kiora's KIO-104 preclinical study for PVR treatment?
When and where will KPRX present their KIO-104 research findings?
What other conditions is KPRX's KIO-104 being tested for?
How does Kiora's KIO-104 work in treating PVR?
